)

Cue Biopharma (CUE) investor relations material
Cue Biopharma Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key product and clinical program updates
Lead dual agonist VK2735 is in two phase 3 trials (VANQUISH 1 and 2) for obesity, with strong enrollment and operational progress reported.
Recent phase 2 oral formulation study showed clear dose response and good efficacy, but high-dose arms had notable adverse events, leading to focus on lower, better-tolerated doses for future studies.
Maintenance market is seen as a major opportunity, with plans for monthly and low-dose oral formulations to support long-term weight loss.
Amylin analog program is advancing, with a pre-IND meeting scheduled and potential for both combination and monotherapy approaches.
Clinical development strategy and regulatory plans
Full phase 2 oral data expected soon; end-of-phase 2 FDA meeting planned to determine next steps, with possible phase 3 initiation in the first half of next year.
Dose selection for future studies will likely focus on 20–80 mg range, with titration and tablet size/count optimization to improve tolerability and retention.
Discontinuation rates in obesity trials are a concern; strategies include offering placebo patients active drug in extension and careful patient selection.
Subcutaneous phase 3 trials are progressing well, with high investigator and patient engagement.
Commercialization and market outlook
Company has doubled in size to support clinical operations, with further growth expected over the next 18–24 months.
Commercial strategy may blend a smaller sales force with a strong online direct-to-patient presence, reflecting evolving obesity market dynamics.
Cash-pay obesity market is expected to remain significant, with flexibility in pricing and access models.
Maintenance therapy and seamless transition between subcutaneous and oral formulations are seen as key differentiators.
Next Cue Biopharma earnings date

Next Cue Biopharma earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage